Research programme: primary biliary cirrhosis therapeutics - GentiBio
Latest Information Update: 24 Nov 2022
At a glance
- Originator GentiBio
- Class Regulatory T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Primary biliary cirrhosis
Most Recent Events
- 18 Nov 2022 Early research in Primary biliary cirrhosis in USA (Parenteral) (Gentibio pipeline, November 2022)